Nguyen Tien Lam

Nguyen Tien Lam

National Hospital for Tropical Diseases Vietnam

Title: HCV/HIV co-infected patients in National Hospital for Tropical Diseases, Vietnam: Genotypes, clinical manifestations and initial results in treating of with Peg-IFN/RBV


Nguyen Tien Lam has completed his medical doctor in 1988 and his MSc of medicine at the age of 32 years from Hanoi Medical University and now is going on PhD at Army Medical Academy, Hanoi, Vietnam. He is the head of viral, parasitic and HIV/AIDS department of National Hospital for Tropical Diseases, the highest level of infectious and tropical diseases including HIV/AIDS, and the secretary of HIV/AIDS care and treatment sub-committee – Ministry of health of Vietnam. He has published about 20 papers in the field of infectious and tropical diseases.


HCV/HIV co-infection is a big health situation among HIV infected patients who shares needle IDU in Vietnam. HCV/HIV co-infected patients quickly progress to cirrhosis and liver cancer and increase hepatotoxic risk due to ARV. Treatment of HCV for HCV/HIV co-infected patients has documented to reduce mortality due to cirrhosis and other related liver diseases caused by HCV. Specific treatment of chronic HCV with Pygelated interferon alpha 2a (Pegasys 180 μg subcutaneous injection, one a week) or Pygelated interferon alpha 2b (Pegintron 1.5 μg/kg subcutaneous injection once a week) combined with Ribavirine (RBV 800mg daily for patients weighted <50 kg and 1000 mg daily for patients weighted ≥50 kg in two divided doses) is a difficult to the HIV infected patients because of their financial problem. The duration of treatment has been ranged from 24, 48 or 72 weeks depending on HCV genotypes and response. Concurrent treatment of Peg-IFN/RBV and ARV requires notes to avoid drug interaction and to reduce adverse sides, so the common ARV regimens are TDF + 3TC + EFV or TDF + 3TC + ATV/r or DRV/r or LPV/r. In Vietnam, because of limited financial resource, there is a little number of HCV/HIV co-infected patients being treated with Peg-IFN/RBV. We conducted a study to analyze HCV genotypes, clinical manifestations and initially to assess response to Peg-IFN/RBV treatment among HCV/HIV co-infected patients in OPC at the National Hospital for Tropical Diseases.

Speaker Presentations

Speaker PDFs

Speaker PPTs

Download PPT